The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Molecular pathogenesis of mantle cell lymphoma
Open accessAbstract
Mantle cell lymphoma is a B cell malignancy in which constitutive dysregulation of cyclin D1 and the cell cycle, disruption of DNA damage response pathways, and activation of cell survival mechanisms contribute to oncogenesis.A small number of tumors lack cyclin D1 overexpression, suggesting that its dysregulation is always not required for tumor initiation.Some cases have hypermutated IGHV and stable karyotypes, a predominant nonnodal disease, and an indolent clinical evolution, which suggests that they may correspond to distinct subtypes of the disease.In this review, we discuss the molecular pathways that contribute to pathogenesis, and how improved understanding of these molecular mechanisms offers new perspectives for the treatment of patients.the European Mantle Cell Lymphoma Network and the Mantle Cell Lymphoma Consortium of the Lymphoma Research Foundation for their continuous collaboration on these projects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramis, G., Jares, P., Beà, S., González-Díaz, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,514
Self-citationMinireview: Cyclin D1: Normal and Abnormal Functions
Fu, M., Wang, C., Li, Z., Sakamaki, T., & Pestell, R. G. (2004) · Endocrinology · doi:10.1210/en.2004-0959 · Cited by 966
Rosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Self-citationWilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · cited 1×
“use of proapoptotic molecules that mimic the activity of BH3-only proteins (105) has shown promising Results in preclinical models (106–108) but no responses or only modest activity in clinical studies (82, 109).”
Friedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., Schaefer-Cutillo, J., De Vos, S., Sinha, R., Leonard, J. P., et al. (2010) · Blood · doi:10.1182/blood-2009-08-236471 · Cited by 747
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri, G., Rasi, S., Rossi, D., Trifonov, V., Khiabanian, H., Ma, J., Grunn, A., Fangazio, M., Capello, D., Monti, S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110921 · Cited by 610
Identification and characterization of circulating human transitional B cells
Sims, G. P., Ettinger, R., Shirota, Y., Yarboro, C. H., Illei, G. G., & Lipsky, P. E. (2005) · Blood · doi:10.1182/blood-2004-11-4284 · Cited by 604
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Pérez-Galán, P., Roué, G., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2006) · Blood · doi:10.1182/blood-2005-05-2091 · Cited by 467
Self-citation
Cited by
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
“Two types of clinically indolent variants are now recognized and reflect, in part, that MCL develops along 2 very different pathways (Figure 2).(31) Classical MCL is usually composed of IGHV-unmutated or minimally mutated B cells that usually express SOX11 and typically involves lymph nodes and other extranodal sites.”
BackgroundSelf-citationArmitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Targeting Bruton's tyrosine kinase in B cell malignancies
Hendriks, R. W., Yuvaraj, S., & Kil, L. P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3702 · Cited by 552
The tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
Beà, S., Valdés-Mas, R., Navarro, A., Salaverria, I., Martín-Garcia, D., Jares, P., Giné, E., Pinyol, M., Royo, C., Nadeu, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314608110 · Cited by 513
Self-citationMantle cell lymphoma: 2013 Update on diagnosis, risk‐stratification, and clinical management
Vose, J. M. (2013) · American Journal of Hematology · doi:10.1002/ajh.23615 · Cited by 328
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Jain, P., & Wang, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25487 · Cited by 274
Cheah, C. Y., Seymour, J. F., & Wang, M. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5904 · Cited by 264
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170
“Accordingly, impaired cell-cycle control in hematopoietic malignancies has been linked to combined deregulation of CDK4 and CDK6 through mechanisms such as inactivation of CDKN2 (also called Ink4) CDK inhibitors and aberrant cyclin D expression.(38,39) In contrast, our findings indicate that MLLrearranged leukemias re…”
Walker, B. A., Wardell, C. P., Johnson, D. C., Kaiser, M. F., Begum, D. B., Dahir, N. B., Ross, F. M., Davies, F. E., Gonzalez, D., & Morgan, G. J. (2013) · Blood · doi:10.1182/blood-2012-12-471888 · Cited by 166
PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers
Li, Y., Chitnis, N., Nakagawa, H., Kita, Y., Natsugoe, S., Yang, Y., Li, Z., Wasik, M., Klein-Szanto, A. J. P., Rustgi, A. K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0625 · Cited by 143
“In this model, D1T286A expression is targeted to the lymphoid compartment by the immunoglobulin enhancer, thereby providing an expression pattern analogous to that observed in human mantle cell lymphoma (MCL) (18).”
InfluentialDrug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective
Li, X., Zhang, Y., Wang, C., Wang, L., Ye, Y., Xue, R., Shi, Y., Su, Q., Zhu, Y., & Wang, L. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c01480 · Cited by 4
Metadata
- Authors
- Jares, P., Colomer, D., & Campo, E.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-10-01
- Volume
- 122
- Issue
- 10
- Pages
- 3416-3423
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2040669551
- Cited by
- 382
- References
- 92
- FWCI
- 19.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.